Similarly, Trametinib forms the backbone of several ongoing glioma clinical trials in combination with the BRAF inhibitor, dabrafenib (GSK-2118436), including pediatric patients with newly diagnosed HGG (NCT03919071) and NF1-LGG or LGG with RAS pathway aberrations (NCT03363217). This evidence concerns the gene BRAF and central nervous system cancer.